(marketscreener.com) Item 1.03. Bankruptcy or Receivership. On October 30, 2023, after considering all strategic alternatives, Gelesis Holdings, Inc. , together with its U. S. subsidiaries, Gelesis, Inc., and Gelesis, LLC, ceased operations and filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United...https://www.marketscreener.com/quote/stock/GELESIS-HOLDINGS-INC-131860759/news/Gelesis-Bankruptcy-Form-8-K-45194973/?utm_medium=RSS&utm_content=20231031
Gelesis is a Massachusetts-based biotechnology company that develops and commercializes novel therapeutics for the treatment of obesity and chronic diseases.